Helicobacter pylori management in non-steroidal anti-inflammatory drug therapy patients in primary care

Internal and Emergency Medicine

Volumn 7, Issue 4, 2012, Pages 331-335

  Zullo, Angelo ^a   Hassan, Cesare ^a   Oliveti, Diodato ^b   Chiriatti, Alberto ^c   Chiuri, Diana Anna Elisa ^b   Marotti, Gemma ^b   Morelli, Lara ^b   Morini, Sergio ^a  

^a NUOVO REGINA MARGHERITA HOSPITAL   (Italy)

^b ASL RMA   (Italy)

^c General Practitioner FIMMG (Italian Federation of General Practitioner)   (Italy)

Author keywords

Clinical practice; Helicobacter pylori; Management; Non steroidal anti inflammatory drug

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGE; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; CROSS-SECTIONAL STUDY; DRUG EFFECT; FEMALE; HELICOBACTER PYLORI; HUMAN; MALE; MIDDLE AGED; PEPTIC ULCER; PRIMARY HEALTH CARE; QUESTIONNAIRE; RISK FACTOR;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CROSS-SECTIONAL STUDIES; FEMALE; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PEPTIC ULCER; PRIMARY HEALTH CARE; QUESTIONNAIRES; RISK FACTORS; YOUNG ADULT;

EID: 84864406778     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-011-0578-7     Document Type: Article

References (26)

1. Mahé I, Leizorovicz A, Caulin C et al (2003) Aspirin for the prevention of cardiovascular events in the elderly. Drugs Aging 20: 999-1010.
2. Davis MP, Srivastava M (2003) Demographics, assessment and management of pain in the elderly. Drugs Aging 20: 23-57.
3. Zullo A, Hassan C, Campo SM et al (2007) Bleeding peptic ulcer in the elderly: risk factors and prevention strategies. Drugs Aging 24: 815-828.
4. Scheiman JM, Hindley CE (2010) Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther 32: 667-677.
5. Graham DY, Chan FKL (2008) NSAIDs, risks, and gastroprotective strategies: current status and future. Gastroenterology 134: 1240-1257.
6. Weil J, Langman MJS, Wainwright P et al (2000) Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 46: 27-31.
7. Lanas A, Garcia-Rodriguez LA, Arroyo MT et al (2006) Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 55: 1731-1738.
8. Kuipers EJ, Malfertheiner P (2004) Helicobacter pylori and nonmalignant diseases. Helicobacter 9(Suppl 1): 29-34.
9. Vergara M, Catalan M, Gisbert JP et al (2005) Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 21: 1411-1418.
10. Sung JJY (2004) Should we eradicate Helicobacter pylori in non-steroidal anti-inflammatory drug users? Aliment Pharmacol Ther 20(Suppl 2): 65-70.
11. Salih BA, Abasiyanik MF, Bayyurt N et al (2007) H. pylori infection and other risk factors associated with peptic ulcers in Turkish patients: a retrospective study. World J Gastroenterol 13: 3245-3248.
12. Huang JQ, Sridhar S, Hunt RH (2002) Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic ulcer disease: a meta-analysis. Lancet 359: 14-22.
13. Papatheodoridis GV, Sougioultzis S, Archimandritis AJ (2006) Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. Clin Gastroenterol Hepatol 4: 130-142.
14. Hunt R, Bazzoli F (2004) Review article: should NSAID/low-dose aspirin takers be tested routinely for H. pylori infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healing. Aliment Pharmacol Ther 19(Suppl 1): 9-16.
15. Rostom A, Moayyedi P, Hunt R (2008) Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risk. Aliment Pharmacol Ther 29: 481-496.
16. Caselli M, Zullo A, Maconi G et al (2007) Cervia II Working Group Report 2006: guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy. Dig Liver Dis 39: 782-789.
17. Hunt R, Fallone C, Veldhuyzan van Zanten S et al (2004) Canadian Helicobacter Study Group Consensus Conference: update on the management of Helicobacter pylori-an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H. pylori infection. Can J Gastroenterol 18: 547-554.
18. Malfertheiner P, Megraud F, O'Morain C et al (2007) Current concepts in the management of Helicobacter pylori infection-the Maastricht III Consensus Report. Gut 56: 772-781.
19. Hernández-Díaz S, Rodríguez LA (2000) Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 160: 2093-2099.
20. Ahsberg K, Hoglund P, von Holstein CS (2010) Mortality from peptic ulcer bleeding: the impact of comorbidity and the use of drugs that promote bleeding. Aliment Pharmacol Ther 32: 801-810.
21. Murray M, Swan AV, Kiryluk S et al (1988) The Hawthorne effect in the measurement of adolescent smoking. J Epidemiol Community Health 42: 304-306.
22. Gatta L, Vakil N, Leandro G et al (2009) Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 104: 3069-3079.
23. Sbrozzi-Vanni A, Zullo A, Di Giulio E et al (2010) Low prevalence of idiopathic peptic ulcer disease: an Italian endoscopic survey. Dig Liver Dis 42: 773-776.
24. Lo Perfido S, Baldo V, Piovesana E et al (2009) Changing trends in acute upper-GI bleeding: a population-based study. Gastrointest Endosc 70: 212-224.
25. Kang JY, Elders A, Majeed A et al (2006) Recent trends in hospital admissions and mortality rates for peptic ulcer in Scotland 1982-2002. Aliment Pharmacol Ther 24: 65-79.
26. Bianco MA, Rotondano G, Buri L et al (2010) Gastro-protective strategies in primary care in Italy: The "Gas. Pro". survey. Dig Liver Dis 42: 359-364.